OTSUKA PHARMACEUTICAL CO LTD
PharmaOTSUKA PHARMACEUTICAL CO LTD is a pharmaceutical company focused on Cardiovascular, Neurology, Dermatology. Key products include SIMTRIYO.
OTSUKA PHARMACEUTICAL CO LTD at a Glance
- Fast trial execution (20 months median completion)
OTSUKA PHARMACEUTICAL CO LTD's Key Drugs
OTSUKA PHARMACEUTICAL CO LTD's core commercial portfolio centers on SIMTRIYO, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
OTSUKA PHARMACEUTICAL CO LTD's Recent FDA Approvals
OTSUKA PHARMACEUTICAL CO LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
OTSUKA PHARMACEUTICAL CO LTD's Therapeutic Areas
OTSUKA PHARMACEUTICAL CO LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OTSUKA PHARMACEUTICAL CO LTD's Top Competitors
OTSUKA PHARMACEUTICAL CO LTD's closest competitors by therapeutic-area and drug-target overlap include Bayer, Pfizer, and OTSUKA. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OTSUKA PHARMACEUTICAL CO LTD Pipeline Snapshot
OTSUKA PHARMACEUTICAL CO LTD has 56 active clinical programs from ClinicalTrials.gov — 26 Phase 3, 12 Phase 2 and 18 Phase 1.
Phase 3 Readout Calendar Pro
7 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SIMTRIYO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • 7 Phase 3 readouts tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 63/89 completed
- • Speed: 20 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-07-24
- Latest
- 2026-07-24
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges